Intercept Pharmaceuticals Inc. (ICPT) Moves Lower on Volume Spike for September 21

Equities Staff  |

Intercept Pharmaceuticals Inc. (ICPT) traded on unusually high volume on Sep. 21, as the stock lost 3.94% to close at $114.17. On the day, Intercept Pharmaceuticals Inc. saw 959,429 shares trade hands on 6,229 trades. Considering that the stock averages only a daily volume of 358,441 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $124.40 and $51.05 over the last 52-weeks, its 50-day SMA is now $105.81, and its 200-day SMA $76.92. Intercept Pharmaceuticals Inc. has a P/B ratio of 23.02.

Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need.

Headquartered in New York, NY, Intercept Pharmaceuticals Inc. has 507 employees and is currently under the leadership of CEO Mark Pruzanski.

For a complete fundamental analysis analysis of Intercept Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for ICPT.

Still paying commissions on stock trades? now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by

To get more information on Intercept Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: ICPT’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change






INTERVIEW: CEO Steve Stanulis - Stanulis Films's Sam Mitchell interviewing CEO Steve Stanulis of Stanulis Films.